Compositions for treating or preventing vasculitis and vasculitis-related diseases
A PBMC supernatant, cultured under radiation stress, addresses the limitations of corticosteroid treatments by inhibiting NETs and protecting endothelial function, providing a safer and more effective approach to treating vasculitis.
Patent Information
- Application Number
- JP2024536323
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-20
- Filing Date
- 2022-12-20
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2042-12-20
AI Technical Summary
Current treatments for vasculitis, primarily based on corticosteroids, have significant side effects and do not address the release of neutrophil extracellular traps (NETs) or protect endothelial integrity, lacking effective preventive or therapeutic options.
A composition comprising a supernatant from a peripheral blood mononuclear cell (PBMC) culture, subjected to radiation during culture, which inhibits NET release and provides endothelial protection.
The PBMC supernatant inhibits NET formation and maintains vascular integrity, offering a safer and more effective treatment or prevention of vasculitis and associated diseases.
Smart Images

Figure 2024544315000001 
Figure 2024544315000002 
Figure 2024544315000003
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions and methods for treating and preventing vasculitis and vasculitis-related diseases. [Background technology]
[0002] Vasculitis is a group of rare diseases of blood vessels, including arteries, veins and lymphatic vessels, resulting in their destruction. Neutrophils are one of the key drivers of vasculitis, affecting endothelial cells by the release of neutrophil extracellular traps (NETs). There are many types of vasculitis, which can vary widely in symptoms, severity and duration. Most types of vasculitis are rare and their causes are generally unknown. Vasculitis can affect both sexes and any age.
[0003] Vasculitis is a systemic disease that affects virtually every organ system, including the skin, lungs, joints, kidneys, gastrointestinal tract, blood, eyes, brain, nerves, sinuses, nose and throat. The pattern of organ involvement is specific to the individual as well as the type of vasculitis.
[0004] Treatment of vasculitis is primarily focused on controlling inflammation and managing any underlying symptoms that may trigger vasculitis. Current treatments are typically based on corticosteroids, such as prednisone. Side effects of corticosteroids can be severe, especially if taken over a long period of time. Possible side effects include weight gain, diabetes, and bone weakening. Other drugs may be prescribed along with the corticosteroid to control inflammation so that the dose of the corticosteroid can be tapered more quickly. The drugs used depend on the type of vasculitis present. These drugs may include methotrexate, azathioprine, mycophenolate, cyclophosphamide, tocilizumab, or rituximab. Occasionally, vasculitis causes aneurysms. Aneurysms may require surgery to reduce the risk of rupture. Blocked arteries may also require surgical procedures to restore blood flow to the affected area.
[0005] All of these medical interventions have side effects and / or certain risks to the health of patients. Moreover, they are all known to target tissue inflammation mainly by affecting T cell function, thereby inhibiting neutrophil recruitment to the endothelium. Treatment options that prevent the release of NETs or protect the endothelium are not available so far. Therefore, the object of the present invention is to provide alternative means and methods for treating or preventing vasculitis and related diseases. Summary of the Invention
[0006] Surprisingly, a composition comprising a supernatant of a PBMC cell culture, the supernatant being obtainable by culturing a PBMC cell culture for at least 4 hours, the PBMC cell culture being subjected to radiation prior to or during the culture, 5 ~1x10 8 It has been found that a composition comprising PBMC / ml can be used for the treatment or prevention of vasculitis.
[0007] In recent years, cell-based therapies have made visible progress in modern regenerative medicine, either to repair damaged tissues and organs, restore their functions, or replace damaged cells. Due to their self-renewal capacity, the possibility to differentiate into several different cell types, and the large number of successful preclinical studies, regenerative therapy with mesenchymal stem cells (MSCs) is considered to be a very promising approach. Despite promising preclinical data, most of the first-in-men clinical trials have failed to show efficacy in patients. Regarding the mode of action (MOA) of MSCs, it has become increasingly clear that paracrine factors released from the injected cells are responsible for many of the beneficial biological effects and thus contribute significantly to tissue regeneration. Due to the considerable limitations of stem cell secretome-based therapies, namely low cell abundance, invasive procedures to obtain the cells, and high costs, alternative sources of cell secretomes with regenerative potential are highly sought after.
[0008] In the past few years, several studies have suggested the secretome of irradiated peripheral blood mononuclear cells (APOSEC) as a beneficial alternative to MSCs. APOSECs exhibit comparable tissue regenerative properties and are more easily obtained compared to paracrine factors released from stem cells (Ankersmit, HJ et al. Eur. J. Clin. Invest. 39 (2009): 445-456). A detailed functional analysis of APOSECs revealed proteins, lipids and extracellular vesicles as the three main biological components. Their MOA are highly diverse and have been tested in many preclinical experimental settings of induced tissue damage.
[0009] It is known that cells, especially mammalian cells, secrete numerous substances into the cell culture medium during culture. The conditioned culture medium so obtained can be used for the treatment and / or prevention of various diseases and disorders. For example, WO 2010 / 070105 and WO 2010 / 079086 disclose conditioned culture medium ("supernatant") obtained by culturing PBMCs and can be used for the treatment of various inflammatory conditions. Thus, as used herein, "supernatant of peripheral blood mononuclear cell (PBMC) cell culture" refers to any supernatant that can be obtained by culturing PBMCs in vitro in a culture medium. After the culturing step, the cultured PBMCs are removed from the culture medium in order to obtain a substantially cell-free, preferably completely cell-free, supernatant. The supernatant of the PBMC culture contains substances produced and secreted by the PBMCs and / or even lysed PBMCs next to the components of the culture medium. "Supernatant" can be used interchangeably with conditioned culture medium that can be obtained by culturing PBMCs.
[0010] It is a surprising discovery that the supernatant of the present invention can inhibit or even prevent the release of NETs involved in the formation of vasculitis. It is also surprising that the supernatant of the present invention exhibits an endothelial protective effect due to its protease inhibitory activity. This helps to maintain vascular integrity and the ability to prevent and / or treat vasculitis.
[0011] Another aspect of the invention is a method of treating vasculitis in a subject in need thereof, comprising administering to the subject a composition comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture, the supernatant being obtainable by culturing the PBMC cell culture for at least 4 hours, the PBMC cell culture being subjected to radiation prior to or during culturing, 5 ~1x10 8 The method relates to a method comprising administering to a subject a subject, the method comprising administering to a subject a subject, the subject being able to receive a sample of the subject's own blood ...
[0012] Yet another aspect of the present invention relates to the use of a composition comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture for the preparation of a medicament for use in the treatment or prevention of vasculitis, the supernatant being obtainable by culturing a PBMC cell culture for at least 4 hours, the PBMC cell culture being subjected to radiation before or during the culture. 5 ~1x10 8 For use, including PBMC / ml. [Brief description of the drawings]
[0013] [Figure 1] We show that APOSEC inhibits serine proteases and prevents thrombin-induced reduction in endothelial barrier function in vitro. [Diagram 2] 1 shows that Aposec prevents NET-induced endothelial tissue damage. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The terms "prevent" and "prevention" as used herein refer to the prevention or inhibition of recurrence, occurrence and development of vasculitis in the human and mammalian body resulting from administration of the supernatant according to the present invention. In some embodiments, "prevent" and "prevention" refer to the reduction of the risk of developing vasculitis. The term "prevent" encompasses not only preventing vasculitis from occurring, but also measures to halt its progression and reduce its consequences once established.
[0015] The terms "treatment" and "treating" as used herein refer to reducing or inhibiting the progression and duration of vasculitis, reducing or ameliorating the severity of vasculitis, and ameliorating one or more symptoms thereof. "Treatment" also encompasses the amelioration and / or amelioration of symptoms of vasculitis. The term "treatment" refers to both therapeutic and prophylactic treatment. For example, those who would benefit from treatment with the compositions and methods of the present invention include those who already have vasculitis as well as those in whom vasculitis is to be prevented.
[0016] As used herein, the term "vasculitis" refers to inflammation of blood vessels (i.e., veins or arteries). Vasculitis may be acute or chronic, hypoimmune or immunological, large ("large vessel vasculitis") or small vessel ("small vessel vasculitis"), and may be primary or secondary to another disorder. Examples of vasculitis include, for example, Behçet's syndrome, Buerger's disease (thromboangiitis obliterans), antineutrophil cytoplasmic autoantibody (ANCA)-associated systemic vasculitis (AASV) (including Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), and Churg-Strauss syndrome (CSS)), cryoglobulinemia, giant cell arteritis (GCA), Henoch-Schönlein purpura, hypersensitivity vasculitis, Kawasaki disease (mucocutaneous lymph node syndrome), polyarteritis nodosa, rheumatic vasculitis, Takayasu's arteritis, and polymyalgia rheumatica (PMR). Vasculitis, including autoimmune vasculitis, can be acute or chronic and can be primary or secondary to another disorder. As used herein, the phrase "autoimmune vasculitis" refers to vasculitis that results from a subject's immune system reacting to one or more self-antigens.
[0017] Vasculitis can affect small, medium and large blood vessels and can occur in vasculitis of the ear-nose-throat (ENT), preferably granulomatous and / or necrotic lesions of the ENT tract, pulmonary hemorrhage, hemoptysis, cutaneous vasculitis, glomerulonephritis, proteinuria, hematuria, focal vasculitis, eosinophilic myocarditis, cardiomyopathy and virus-associated vasculitis. Vasculitis also plays a role in acute respiratory distress syndrome (ARDS), caused by, for example, viral infections such as Sars-CoV2. Therefore, it is particularly preferred to use the composition of the present invention for the treatment and / or prevention of ARDS, particularly ARDS caused by Sars-CoV2.
[0018] According to a further preferred embodiment of the invention, the PBMCs are cultured in a cell growth medium, preferably a CellGro medium, more preferably a cell culture medium selected from the group consisting of Cellgro GMP DC medium, RPMI, DMEM, X-vivo and Ultraculture.
[0019] According to the invention, the PBMCs of the PBMC cell culture are subjected to stress-inducing conditions before or during culture.
[0020] The term "stress-inducing conditions" as used herein refers to culture conditions that result in stressed cells. Conditions that cause stress to cells include at least any type of radiation (e.g., ionizing radiation such as UV radiation, gamma radiation, etc.), preferably ionizing radiation or UV radiation. However, cells may be further subjected to heat, chemicals, hypoxia, osmotic pressure, pH shifts, etc., which may cause additional stress to cells.
[0021] Thus, stress-inducing conditions may also include hypoxia, ozone, heat (e.g., temperatures 2°C higher, preferably 5°C higher, more preferably 10°C higher than the optimal culture temperature for PBMCs, i.e., 37°C), chemicals, osmolarity (i.e., osmolarity conditions that are reduced by at least 10% compared to the osmolarity conditions that regularly occur in body fluids, particularly blood), or combinations thereof.
[0022] According to another preferred embodiment of the invention, the PBMCs are subjected to ionizing radiation, preferably gamma radiation, at a dose of at least 10 Gy, preferably at least 20 Gy, more preferably at least 30 Gy, more preferably at least 40 Gy, more preferably at least 50 Gy.
[0023] According to a preferred embodiment of the invention, the PBMCs are cultured for at least 6 hours, preferably at least 12 hours, before isolating the supernatant thereof.
[0024] According to a preferred embodiment of the present invention, the PBMC cell culture comprises 1x10 6 ~1x10 7 PBMC / ml, preferably 2x10 6 ~25x10 6 Contains PBMCs / ml.
[0025] It has been found that the composition of the supernatant obtainable by culturing PBMCs exhibits advantageous properties when culturing a certain amount of PBMCs per ml of cell culture medium.
[0026] According to another preferred embodiment of the present invention, 0.1 to 5 ml of supernatant / kg body weight, preferably 0.3 to 3 ml / kg body weight, more preferably 0.5 to 2 ml / kg body weight, more preferably 0.8 to 1.2 ml / kg body weight is administered to the human or animal mammalian body.
[0027] The composition of the present invention comprises a sufficient amount of the supernatant to treat or prevent vasculitis and diseases related to vasculitis. The volume of the supernatant administered per kg body weight to a human or mammal as described above refers directly to the supernatant. If the volume is too large to be administered to the human or mammal body, this volume can be reduced, for example, by lyophilization. Therefore, the volume of the composition of the present invention administered may be lower than the volume indicated for the supernatant. Those skilled in the art know how much volume can be administered using a specific administration route.
[0028] According to preferred embodiments of the present invention, the compositions are administered by inhalation, topically, orally, sublingually, buccally, subcutaneously or intravenously, whereby it is most preferred to administer the compositions of the present invention intravenously.
[0029] The composition of the present invention may contain pharma- ceutically acceptable excipients such as diluents, stabilizers, carriers, etc. Depending on the dosage form, the preparation according to the present invention contains the respective components. Methods for preparing the same are well known to those skilled in the art.
[0030] To extend the shelf life of the compositions according to the invention, the supernatant or even the complete composition can be lyophilized. Methods for lyophilizing such preparations are well known to those skilled in the art.
[0031] Prior to its use, the lyophilized preparation can be contacted with water or an aqueous solution containing buffers, stabilizers, salts, and the like.
[0032] According to another preferred embodiment of the invention, the mammal is a horse, a dog, a cat or a camel.
[0033] The compositions of the present invention can be used to treat any type of mammal, however the aforementioned mammals are most preferred.
[0034] Another aspect of the invention relates to a method for treating or preventing vasculitis comprising administering a composition as defined above. EXAMPLES
[0035] This example demonstrates that APOSEC protects against vascular inflammation and injury by a dual mechanism: 1) APOSEC inhibits the induction of NETs, thereby preventing NET-induced vasculitis, and 2) APOSEC directly prevents vascular leakage.
[0036] Materials and Methods Isolation of PBMCs and generation of PBMC secretome APOSEC was produced by the Austrian Red Cross, Transfusion Service of Upper Austria (Austria) in compliance with Good Manufacturing Practice (GMP). Briefly, PBMCs were obtained by Ficoll-Paque PLUS (GE Healthcare, USA)-assisted density gradient centrifugation and exposed to 60 Gy of cesium-137 gamma irradiation (IBL 437C, Isotopen Diagnostik CIS GmbH, Germany). Cells were cultured at 2.5 × 10 7 The secretomes were adjusted to a concentration of 1000 cells / mL (equivalent to 25 U / ml) and cultured for 24 h in CellGenix GMP DC medium without phenol red (CellGenix GmbH, Germany). Cells and cell debris were removed by centrifugation and the supernatant was passed through a 0.2 μm filter. Methylene blue treatment was performed for viral clearance. Secretomes were lyophilized, terminally sterilized by high-dose gamma irradiation, and stored frozen.
[0037] Protease activity assay To test the inhibitory effect of APOSEC on protease activity, a fluorescent enzyme activity assay (Enzcheck) was performed using the non-selective serine protease trypsin (Gibco) at a concentration of 0.05%. The PBMCsec stock concentration was set at 12.5 U / ml according to the manufacturer's instructions.
[0038] Transendothelial Electrical Resistance (TEER) The change in electrical impedance of dermal microvascular endothelial cells (DMECs) was measured using an ECIS system (Applied Biophysics). A total of 4000 cells / cm were placed in each well of an ECIS chamber (ibidi GmbH, Germany). 2Cells were seeded at 1000 x g for 24 h. Upon reaching full confluence, cells were treated with thrombin and thrombin combined with control medium (concentrated at 12.5 U / ml) or APOSEC (concentrated at 12.5 U / ml), respectively. Endothelial resistance was monitored at 250 Hz for 2 h after the addition of treatment according to a previously published protocol (Schossleitner, K. et al. Arter. Thromb Vasc Biol 36 (2016): 647-654).
[0039] Co-culture of endothelial cells and neutrophils Neutrophils were isolated from healthy donors and stimulated with ionomycin to induce NET formation in the presence or absence of APOSEC. Cells were incubated with the respective treatments together for 1 h at 37 °C and subsequently washed with PBS before being added to primary human umbilical vein endothelial cells (HUVEC). Co-culture was performed either by adding neutrophils directly to a confluent HUVEC monolayer or by separating the two cell populations by a transwell insert providing a physical barrier with a 0,4 μm mesh / filter. After 2 h, neutrophils were removed and HUVEC were cultured for 24 h under standard conditions. Cell culture supernatants of HUVEC were obtained and stored at -20 °C until further processing.
[0040] ELISA Enzyme-linked immunosorbent assays (ELISAs) for common proinflammatory cytokines and activation markers associated with injured or damaged endothelial tissue (all from R&D Systems, USA) were performed according to the manufacturer's instructions. citH3 ELISA (clone 11D3, Cay501620-96, Caymen) was performed as recommended by the manufacturer.
[0041] Flow cytometry Flow cytometry evaluation was routinely performed on a FACSCalibur (BD Biosciences, USA) as recommended by the manufacturer. To evaluate nematosis, triple staining with CD66b-Pacific Blue (Biolegend, USA), CD15-PE-Cy7 (Biolegend) and citH3-FITC (Abcam, UK) was performed.
[0042] result APOSEC inhibits serine proteases and prevents protease-induced vascular leakage To investigate the potency of APOSEC in inhibiting serine protease activity, we performed a protease activity assay against the serine protease trypsin. While control medium showed a negligible inhibitory effect on protease activity (3.72%), the addition of APOSEC led to a 41.96% inhibition of the enzymatic activity of trypsin (Figure 1A). We then also investigated whether APOSEC interfered with thrombin-induced disruption of the endothelial barrier as measured by electrical resistance. While basal medium alone showed no effect, the addition of thrombin led to a strong decrease in endothelial resistance. This decrease was significantly reduced by the addition of APOSEC. The addition of control medium only showed a weak effect on endothelial resistance (Figure 1B).
[0043] In detail, Figure 1 shows that APOSEC inhibits serine proteases and prevents thrombin-induced reduction of endothelial barrier function in vitro. According to Figure 1A, APOSEC significantly inhibits the enzymatic activity of trypsin after 60 min when compared to control medium (control medium 3.72% vs. 41.96% relative inhibition of trypsin activity, p-value = 0.0002). According to Figure 1B, dermal microvascular endothelial cells (DMEC) showed a reduction in barrier function after treatment with the serine protease thrombin when compared to basal medium (basal medium 1 vs. 0.29 thrombin). The combination of thrombin with control medium resulted in a comparable reduction of APOSEC to thrombin (basal medium 1 vs. 0.38 thrombin + control medium), while the addition of APOSEC to thrombin showed a significantly lower reduction (basal medium 1 vs. 87.5 thrombin + Aposec), preventing the disruption of the endothelial barrier. Barrier function of thrombin + Aposec was significantly higher than that of thrombin (p-value = 0.0071) and thrombin + control medium (p-value = 0.0126).
[0044] APOSEC inhibits NET formation and NET-induced activation of endothelial cells To investigate whether APOSEC affects ionomycin-induced NET formation, whole blood was stimulated with ionomycin in the absence or presence of APOSEC. The induction of citrullinated histone-3 (CitH3), a specific marker of NET formation, was measured by flow cytometry (Figure 2A) and ELISA (Figure 2B). In both assays, a strong reduction in ionomycin-induced histone citrullination was observed (Figure 2A and B). Next, we investigated the effect of APOSEC on NET-induced endothelial tissue damage in an in vitro coculture model. To evaluate whether direct contact of activated neutrophils is necessary for endothelial cell activation and damage, we established cocultures with either direct contact between neutrophils and endothelial cells (Figure 2D) or a physical barrier between them in the form of a transwell insert (Figure 2C). The physical barrier appeared to be sufficient to block the pro-inflammatory effects of neutrophils on endothelial cells as well as their tissue-damaging capabilities, as shown in Figure 2C. However, direct contact between ionomycin-activated neutrophils and endothelial cells significantly increased the production of pro-inflammatory cytokines, including interleukin (IL)-6, IL-8, and tumor necrosis factor alpha (TNFα), as well as endothelial activation markers such as intercellular adhesion molecule 1 (ICAM-1) (Figure 2D). Treatment of activated neutrophils with APOSEC prior to addition to endothelial cells almost completely abolished the inflammatory response of endothelial cells, with cytokine levels similar to those of untreated cells (Figure 2D).
[0045] Figure 2 shows that Aposec prevents NET-induced endothelial tissue damage. In Figure 2A, flow cytometry analysis (n=3) of whole blood samples stimulated with ionomycin and treated with APOSEC is shown. In Figure 2B, ELISA (n=2) of citrullinated histone h3 (citH3) of whole blood samples stimulated with ionomycin and treated with APOSEC is shown. In Figure 2C and Figure 2D, ELISA of pro-inflammatory cytokines and activation markers of HUVEC derived from neutrophil-HUVEC co-cultures using either transwell inserts as a barrier between cell populations (Figure 2C) or direct contact (Figure 2D). Treatment conditions are indicated below each graph with - and +. IL6, interleukin-6; IL8, interleukin-8; TNF-α, tumor necrosis factor α; ICAM-1, intracellular adhesion molecule 1; -, absent; +, present.
[0046] conclusion Taken together, the above data indicate that APOSEC can reduce vascular damage by inhibiting the enzymatic destruction of vascular integrity and by inhibiting NET release by neutrophils. These mechanisms are involved in a variety of severe diseases, including all types of vasculitis, granulomatous or necrotic lesions of the ENT-tract, pulmonary hemorrhage and hemoptysis, punctate or rash associated with necrotizing cutaneous vasculitis, glomerulonephritis and proteinuria, hematuria, focal vasculitis of the neurotrophic vessels affecting the peripheral nervous system, eosinophilic myocarditis and cardiomyopathy, and Covid-19, all of which may benefit from the application of APOSEC.
Claims
1. A composition for use in the treatment or prevention of vasculitis comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture, the supernatant being obtainable by culturing a PBMC cell culture for at least 4 hours, the PBMC cell culture being subjected to radiation before or during the culture. 5 ~1x10 8 A composition comprising PBMCs / ml.
2. 2. The composition for use according to claim 1, which is administered subcutaneously, intramuscularly, subdermally, intradermally or intravenously.
3. The composition for use according to claim 1 or 2, wherein the PBMC cell culture comprises monocytes, T cells, B cells and / or NK cells.
4. The composition for use according to any one of claims 1 to 3, wherein the PBMCs are cultured in a cell culture medium selected from the group consisting of a cell growth medium, preferably CellGro medium, more preferably Cellgro GMP DC medium, RPMI, DMEM, X-vivo and Ultraculture.
5. 5. The composition for use according to any one of claims 1 to 4, wherein the PMC is subjected to ionising radiation at a dose of at least 10 Gy, preferably at least 20 Gy, more preferably at least 30 Gy, more preferably at least 40 Gy, more preferably at least 50 Gy.
6. The composition for use according to any one of claims 1 to 5, wherein the PBMCs are cultured for at least 6 hours, preferably at least 12 hours, more preferably at least 24 hours before isolating the supernatant thereof.
7. PCBMC cell cultures were cultured at 1x10 6 ~1x10 7 PBMC / ml, preferably 2x10 6 ~25x10 6 The composition for use according to any one of claims 1 to 6, comprising PBMCs / ml.
Citation Information
Patent Citations
Composition for treating or preventing an allergy or allergic reaction
EP3842064A1
Pharmaceutical preparation
US20110250190A1
Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
US20120045418A1
